Feed Articles

Drastic drop in Novo Nordisk shares! Weak results of new drug shocked

Shares in Danish pharmaceutical company Novo Nordisk A/S have seen their biggest drop since December. The reason is the poor results of a clinical trial of their new injection CagriSema, which was supposed to be the next step in the treatment of diabetes and obesity. Although patients with diabetes lost an average of 15.7% of their weight, investors' expectations were higher.

Novo Nordisk $NVO reported Monday that patients who followed CagriSema treatment lost an average of 15.7% of their body weight over 68 weeks. By comparison, patients taking a placebo lost only 3.1% of their weight. However, taking all study participants into account, the weight loss was only 13.7%, which is less than investors had hoped for.

Analysts had expected figures closer to 20%, said David Evans of Kepler Cheuvreux. This is the second disappointment linked to the drug - a study last December targeting patients with obesity but no diabetes also failed to deliver the expected results. This raises doubts about the future success of CagriSema, especially in competition with Eli Lilly & Co's Zepbound.

Novo Nordisk shares fell as much as 8.8% in Copenhagen in response to the news, the steepest decline since the first CagriSema study was published on 20 December. Overall, the company's shares have lost about 38% over the past 12 months, reflecting investor concerns about Novo Nordisk's long-term competitiveness in the weight-loss drug market.

The dosing problem

GLP-1 hormone-based drugs, such as Novo Nordisk's Wegovy, generally have less effect on weight loss in patients with diabetes. The difference tends to be around 30-35%, Jefferies analysts said. Investors had hoped that CagriSema would overcome this tendency with the addition of an active ingredient, but the results don't suggest that.

Patients in the study were able to choose their dosage, with less than two-thirds reaching the highest dose. A similar trend was seen in a previous study targeting obese patients, where many chose lower dosages, which may have affected the overall results.

According to Bloomberg analyst Michael Shah, CagriSema's results are similar to rival drug Zepbound, raising concerns about whether Novo Nordisk can differentiate itself significantly in the market. However, the study's design, which allowed patients to choose their doses, may have partially misrepresented the drug's true potential.

Novo Nordisk plans to apply for initial regulatory approval

The drug could be on the market by early 2027 and peak annual sales could reach $10 billion. That's significantly less than expected for existing blockbusters like Ozempic or Wegova.

Disclaimer: You will find a lot of inspiration on Bulios, but stock selection and portfolio construction is up to you, so always do a thorough analysis of your own.

Source: Yahoo Finance

Stocks mentioned

A community member's personal view, not investment advice. Community Guidelines

Follow Bulios on Google News

Be among the first to discover new analyses, news and market moves.

Follow

Recommended articles

Read more

Expensive oil was supposed to sink them; these 3 cruise lines instead report records and expect further growth

Oil this year soared to $138 per barrel, and cruise ships, which burn hundreds of thousands of tons of it annually, were supposed to be the first to suffer. Instead, all three largest cruise operators raised their profit outlooks, yet for a dollar of profit the market pays almost twice as much for…

MC
Milan Charvat
· 6h
Read more
BLACK

Man with Parkinson's stood up and walked away after an injection. The drugmaker's stock still fell 20%

A man with Parkinson's who couldn't get up from a chair walked out through the door on his own after a year of treatment with his own cells. The company behind the treatment raised $140.6 million in its IPO, and three weeks later its stock is 20% cheaper, even though there hasn't been a single…

MC
Milan Charvat
· 10h
Read more
BLACK

Dividends Above 10%? No Problem for These Stocks

A yield of over 15% a year sounds almost unbelievable in the stock market, yet several established US-listed securities are offering just that today. Mortgage REITs and leveraged bond funds earn money from the difference between the yield on mortgages or bonds and the cost of short-term financing,…

KJ
Kryštof Jáně
· 13h

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy